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Abstract
Ten years ago the sleep disorder narcolepsy was linked to the neuropeptide hypocretin (HCRT), also known as orexin. This
disorder is characterized by excessive day time sleepiness, inappropriate triggering of rapid-eye movement (REM) sleep and
cataplexy, which is a sudden loss of muscle tone during waking. It is still not known how HCRT regulates REM sleep or
muscle tone since HCRT neurons are localized only in the lateral hypothalamus while REM sleep and muscle atonia are
generated from the brainstem. To identify a potential neuronal circuit, the neurotoxin hypocretin-2-saporin (HCRT2-SAP)
was used to lesion neurons in the ventral lateral periaquaductal gray (vlPAG). The first experiment utilized hypocretin knock-
out (HCRT-ko) mice with the expectation that deletion of both HCRT and its target neurons would exacerbate narcoleptic
symptoms. Indeed, HCRT-ko mice (n=8) given the neurotoxin HCRT2-SAP (16.5 ng/23nl/sec each side) in the vlPAG had
levels of REM sleep and sleep fragmentation that were considerably higher compared to HCRT-ko given saline (+39%; n=7)
or wildtype mice (+177%; n=9). However, cataplexy attacks did not increase, nor were levels of wake or non-REM sleep
changed. Experiment 2 determined the effects in mice where HCRT was present but the downstream target neurons in the
vlPAG were deleted by the neurotoxin. This experiment utilized an FVB-transgenic strain of mice where eGFP identifies
GABA neurons. We verified this and also determined that eGFP neurons were immunopositive for the HCRT-2 receptor.
vlPAG lesions in these mice increased REM sleep (+79% versus saline controls) and it was significantly correlated (r=0.89)
with loss of eGFP neurons. These results identify the vlPAG as one site that loses its inhibitory control over REM sleep, but
does not cause cataplexy, as a result of hypocretin deficiency.
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Introduction
Neurons containing the neuropeptide hypocretin (HCRT), also
known as orexin are located in the lateral hypothalamus and
hypothesized to inhibit REM sleep [1,2]. When these neurons are
destroyed, either genetically [3–5] or through a chemical neuro-
toxin [6], REM sleep is enhanced. In humans, loss of HCRT
neurons is associated with the sleep disorder narcolepsy and
inappropriate triggering of REM sleep [1,2]. There are two HCRT
receptors (hypocretin-1 and 2 receptors) and in canine narcolepsy,
the REMsleep abnormality results from a mutation inthe HCRT-2
receptor [7]. Hypocretin-2 receptor knockout mice display
narcoleptic behavior [8].
It is not known how HCRT regulates REM sleep. One
possibility is that HCRT mediates its action via HCRT target
neurons in the pons since REM sleep is generated from there
[9,10]. One hypothesized hypocretin target in the pons is the
ventral sub lateral-dorsal region (vSLD), which is ventral to the
locus coeruleus [11]. Lesions of HCRT receptor bearing neurons
in this area in rats does increase REM sleep (56%) [12]. A second
site is the ventral lateral periaquaductal gray (vlPAG) area where it
is also hypothesized that neurons inhibitory to REM sleep are
localized [13]. In cats, electrolytic lesions of the vlPAG [14] or
microinjection of muscimol into the vlPAG [15] produces a long
lasting increase in REM sleep. In rats, ibotenic acid induced
nonspecific lesions of the vlPAG increases REM sleep [16].
The effects of lesions of this area on REM sleep have never been
determined in mice. The benefits of using mice are that a murine
model of narcolepsy exists and it provides a valuable tool to identify
the circuitry underlying the disease. Moreover, transgenic mouse
models exist where a reporter gene, such as green fluorescent
protein (GFP), marks a specific phenotype of neurons and these
could be used to ferret out the pharmacology of the vlPAG neurons.
Therefore,thepresentstudyteststhe hypothesisthat vlPAGneurons
are inhibitory to REM sleep by destroying these neurons and
determining whether there is an increase in REM sleep. To destroy
the vlPAG neurons a novel neurotoxin, hypocretin-2 conjugated to
saporin (HCRT2-SAP), is used. The results reveal that vlPAG
lesioned mice have a significant increase in REM sleep thereby
identifying a hypocretin-to-vlPAG circuit that inhibits REM sleep.
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Experiment 1: Effects of vlPAG lesions in HCRT-null mice
Animals. Mice (20–35 g) homozygous with respect to the
deletion of the hypocretin gene on both alleles (HCRT-ko n=18)
were identified through PCR of tail snips. Heterozygote mice were
not used as they do not display narcoleptic behavior [17]. HCRT-
ko mice were obtained from Dr. Masashi Yanagisawa and Dr.
Takeshi Sakurai and a breeding colony was established in our
facility at the VA Boston Healthcare System in West Roxbury.
The mice have been backcrossed for more than 20 generations on
a C57BL/6J line and are congenic with respect to the C57BL/6J
strain. Our recently published data from wildtype (C57BL/6J)
mice (n=9) were also used and provided a record of the normal
sleep-wake pattern in this strain for comparison [18]. The WT
mice were recorded at the same time and under the same
conditions as the other mice in this study. The methods used to
record and analyze the sleep data were the same for all mice. All
animals were maintained on a 12:12 h light-dark cycle with ad-
libitum access to water and food. All experiments were conducted
as per the guidelines of the American Association for the
Accreditation of Laboratory Animal Care (AAALAC) and
approved by the VA Boston Healthcare System’s Institution
Animal Care and Use Committee (IACUC).
Surgical procedures. Mice were implanted with sleep
recording electrodes under isofluorane (4% for induction; 1.5% for
maintenance) anesthesia as described previously [19]. Briefly, four
jeweler’sscrewswere insertedinto theskull(twoeachatopthe frontal
and occipital cortex) and were used to record the electroen-
cephalogram(EEG).Twoflexiblewireswereinsertedintothenuchal
muscles and recorded the electromyogram (EMG). These electrodes
were inserted into a plastic plug and secured to the skull with dental
cement. The head of the mouse was adjusted on the nose bar so that
bregma and lambda were at level height. At this time a single glass
pipette (10–15 mm, tip diameter) was lowered into the vlPAG
target area (relative to bregma)(anterior-posterior=25.0; medial-
lateral=60.8 mm; ventral to dura=22.5 mm) [20] and either
HCRT2-SAP (n=11; 16.5 ng/23 nl/sec each side; Advanced
Targeting Systems, San Diego, CA) or saline (n=7; 0.9%, 23 nl/
sec each side) were injected by a nanoliter pump (Nanoliter 2000,
World Precision Instruments Inc., Sarasota, Fl). The glass pipette
was left in place for a minute and then slowly withdrawn. Once
outside the brain the patency of the pipette was confirmed by the
appearance of a small droplet of either HCRT-SAP or saline at the
tip of the pipette. HCRT2-SAP or saline were applied bilaterally to
the vlPAG.
Recording of sleep and analysis of sleep data. After
surgery all mice were housed singly in plastic cages with corn
bedding. A week after surgery the mice were connected to flexible
cables for recording sleep. Fifteen days after the injection the
animal’s sleep-wake patterns were recorded for 48 h.
The temperature in the sleep recording room was 22–24uC and
a 12:12 h light-dark cycle (7AM-7PM lights on; 100 lux) was
maintained. Contralateral frontal-occipital EEG screw electrodes
were used for EEG acquisition. The EEG data was filtered at
70 Hz (low pass filter) and 0.3 KHz (high pass filter) using a Grass
polygraph and continuously sampled by the data acquisition
program (Icelus software, developed by Mark Opp, University of
Michigan, Ann Arbor, MI) at sampling rate of 128 Hz.
The EEG and EMG recordings were scored manually on a
computer (Icelus software; Mark Opp, Univ Michigan, Ann
Arbor, Michigan, USA) in 12 second epochs for wake, non-REM
sleep and REM sleep by staff blind to the treatment. Wakefulness
was identified by the presence of desynchronized EEG and high
EMG activity. Non-REM sleep consisted of high amplitude slow
waves together with a low EMG tone relative to waking. REM
sleep was identified by the presence of regular EEG theta activity
coupled with low EMG relative to slow wave sleep. After the EEG
data were scored, the code was broken to reveal the identity of
each mouse. The percent of time spent in wakefulness, non-REM
and REM was determined for each hour. Two way-ANOVA
followed by Holm-Sidak post-hoc test for multiple comparisons
was used to compare changes in sleep parameters within the
genotypes for the different treatment groups. Statistical signifi-
cance was evaluated at the P,0.05 level.
The EEG and EMG recordings were also examined for signs of
cataplexy, which is defined as a sudden loss of muscle tone during an
awake episode. A previously described criteria was used for identifi-
cation of cataplexy episodes [17,18]. Cataplexy was identified if the
mouse was awake for more than 2 minutes and then experienced a
sudden loss of muscle tone. During these bouts, the EEG had
diminished delta activity and predominant theta activity.
Immunohistochemistry to identify site of lesion. At the
end of the experiment, the mice were euthanized (overdose of
pentobarbital) and perfused transcardially with 20 ml phosphate-
buffered saline at room temperature followed by 50 ml
paraformaldehyde (4%) in phosphate buffer. The brains were
removed and post fixed overnight in the same fixative and then
transferred to 30% sucrose until it equilibrated. The brains were
cut in a cryostat and 40 m thick coronal sections obtained (1 in 4
series). The free floating sections were immunostained for NeuN
(mouse anti-NeuN, MAB377, 1: 1K; Millipore, MA), followed by
biotinylated-secondary antibodies. The secondary antibodies were
visualized using ABC- DAB procedure. In HCRT-ko mice loss of
NeuN staining demarcated the lesioned area and traced onto
paper using a drawing tube attached to a microscope (Nikon
Eclipse E400).
Experiment 2: vlPAG lesions in FVB-GFP transgenic mice
Mice homozygous for the FVB-TgN (GadGFP) 45704Swn
transgene, on a FVB background (FVB-GFP; n=20; Jackson
Laboratories, Bar Harbor, ME, USA) were used. These mice
express enhanced green fluorescent protein (eGFP) under the
control of the mouse Gad1 gene promoter, thereby revealing the
GABA neurons [21].
These mice were implanted with sleep recording electrodes, and
HCRT2-SAP (n=12) or saline (n=8) were microinjected into the
vlPAG as described in experiment 1. The sleep recording
procedure, and data analysis were same as in experiment 1.
At the end of the experiment all animals were euthanized
(overdose of pentobarbital), perfused and the brains were removed.
The brains were cut as mentioned above in experiment 1 and the
free floating sections were immunostained for GFP (rabbit anti-
GFP, 1: 20K; Millipore, MA) and NeuN (mouse anti-NeuN,
MAB377, 1: 1K; Millipore, MA), followed by the respective
biotinylated-secondary antibodies. The secondary reaction for the
GFP was then visualized using the ABC-DAB and for visualizing
the NeuN, we used ABC-AP Vector Red (SK-5100, Vector Labs,
Burlingame, CA). Extent of lesion was marked by the boundary of
the neuronal loss as seen by the NeuN staining and loss of the GFP
neurons. The spread of the GFP neurons in the vlPAG area were
plotted using a drawing tube and counted in both the lesion and
control groups. GFP neurons were counted in every fourth section
at three levels (AP levels24.9 to 5.2) on both sides and averaged
for each hemisphere.
Some of the FVB-GFP mice were injected with colchicine
(3 mg/kg i.p.) and euthanized (overdose of pentobarbital) after 7
days (fixation as described in experiment 1). The sections from
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(guineapig anti-GABA, NT-108 1:1K; Protos Biotech Corp,
NY), followed by the secondary conjugated to Alexa 568 (Goat
anti Guineapig; Jackson Immunoresearch Laboratories, West
grove, PA). Stained sections were then visualized and the images
acquired using a confocal microscope (Nikon Eclipse TE 200-U
microscope, Nikon Corporation, Melville, NY, USA) to identify
the colocalization of GFP in GABA positive cells.
In tissue sections from the FVB mice stained with hypocretin
antibody (goat anti-HCRT, sc8070, 1:500, Santa Cruz Biotech-
nology, Santa Cruz, CA) we observed abundant HCRT fibers and
terminals in the vicinity of the GFP positive neurons in the vlPAG
area. Therefore, we also investigated if the HCRT-2 receptors are
present on these neurons. Some sections from the FVB-GFP mice
were treated with primary antibody to HCRT- receptor 2 (Goat
anti-HCRT-R-2, sc 8074, 1:50; Santa Cruz Biotechnology, Santa
Cruz, CA) followed by the donkey anti goat secondary conjugated
to Alexa-568 (Jackson Immunoresearch Laboratories, West grove,
PA). The specificity of the HCRT-receptor 2 antibody has been
demonstrated [22]. The images were then acquired and viewed
using a confocal microscope.
Experiment 3: Inputs to the vlPAG
To investigate the areas projecting to the vlPAG, the retrograde
tracer, cholera toxin subunit b (23 nl; CTb 0.5%; List Biological
Laboratories Inc.) was injected in the vlPAG in some of the mice
(FVB-GFP; n=8). One week later the mice were sacrificed (after
overdose of pentobarbital), brains perfused, and tissue sections
processed for immunohistochemistry (Goat anti CTb, 1:30K, List
Biological Laboratories Inc., CA) followed by the biotinylated
secondary antibody, which was then visualized using the ABC-
DAB procedure. Two of the wells from these injected mice were
then also processed for the immunoreaction for the CTb (Goat
anti CTb, 1:2K, List Biological Laboratories Inc., CA), where
CTb was visualized using secondary conjugated to alexa 568
(Jackson Immunoresearch Laboratories, West grove, PA). Follow-
ing this reaction, one of these wells was then processed for a
second reaction with hypocretin (rabbit anti HCRT sc8070, 1:500,
Santa Cruz Biotechnology, Santa Cruz, CA) and the other well for
melanin concentrating hormone (Rabbit anti MCH, H-070-47,
1:5K, Phoenix Pharmaceuticals Inc, Burlingame, CA). In these
both hypocretin and MCH were visualized using the secondary
antibody conjugated to the alexa 647 (Jackson Immunoresearch
Laboratories, West grove, PA).
One of four series of sections was used to count the retrogradely
labeled CTb cells on both sides of the hemisphere using a
brightfield microscope at 10X magnification. The areas were
identified based on established neural landmarks in mice [20].
Some of the areas with heaviest projections to the injection site
involved counting two or three sections, which were then added to
calculate the total number of projections to a targeted area.
Results
Experiment 1: Effects of vlPAG lesions in HCRT-ko mice
Extent of lesions in HCRT-ko mice. In 8 of 11 mice
HCRT2-SAP (16.5 ng/23 nl) induced lesions were localized to the
vlPAG (fig. 1A-H). In the other three micethe lesions were off-target
as follows: in one mouse the lesion was ventral (mouse F736); in
another the lesion was dorsal to vlPAG (mouse F735); the third
mouse had a unilateral lesion in vlPAG (mouse M621) (fig. 1-I).
Figure 2 is a photomicrograph of lesion in the vlPAG as defined by
loss of NeuN staining in a representative HCRT-ko mouse. In a
separate group of eight WT mice (C57BL/6J), a microinjection of
unconjugated saporin (16.5 ng/23 nl) was made to the vlPAG and
observable neuronal loss such as that seen with the conjugated
saporin (HCRT2-SAP)(figure2)wasnot seen(Supplementaryfigure
S1), which is consistent with other reports [23,24].
Effect of HCRT2-SAP lesions of the vlPAG on sleep in
HCRT-ko mice. HCRT-ko mice with lesions of the vlPAG area
(n=8) had a significant increase in percentage of REM sleep (two-
way ANOVA, for treatment6day/night, F2, 42=4.97, P=0.012)
during the night phase compared to saline in HCRT-ko mice
(n=7) or wildtype-C57BL/6J mice (n=9) (fig. 3A and B). HCRT-
ko mice already have more REM sleep at night compared to WT
mice (99.63%), and the lesions increased it further (+177% versus
WT; +39% versus HCRT-ko). Over the 24 h period REM sleep
was increased by 20.34% compared to HCRT-ko mice given
saline. The lesions had no significant effect on the percentage of
non-REM and wake states compared to the HCRT-ko mice given
saline (fig. 3C-F). There were no significant effects on REM, non-
REM sleep and wake during the day between the two treatment
groups of the HCRT-ko mice. The HCRT-ko mice (both saline
and lesioned) had significant increase in non-REM (F2, 42=7.313,
P=0.002) and decrease in wake (F2, 42=8.245, P=,0.001)
during the night phase compared to the wildtype- C57BL/6J mice
(fig. 3C- F). Thus, vlPAG lesions in HCRT-ko mice exacerbated
the increase in REM sleep but not the wake or non-REM sleep
changes.
HCRT-ko mice have a more fragmented sleep-wake architec-
ture compared to WT mice [17]. HCRT2-SAP lesions of the
vlPAG in the HCRT-ko mice further destabilized the sleep
architecture. Lesioned HCRT-ko mice had significantly more
bouts of REM (F1, 26=5.99, P=0.018), non-REM (F1, 26=5.109,
P=0.028) and wake (F1, 26=5.60, P=0.022) during the night
phase compared to the HCRT-ko mice injected with saline group
(Table-1). This was a result of an increase in the number of short
(,1.3 minutes) bouts of REM sleep (F1, 13=4.061, P,0.001), non-
REM (F1, 13=15.017, P,0.001), and wake (F1, 13=6.328;
p,0.001) compared to the saline injected HCRT-ko mice (fig. 4).
In the lesioned mice, the average length of REM sleep bouts did
not change at night compared to HCRT-ko mice given saline, but
the average length of the non-REM (F1, 26=12.35, P=0.002) and
wake bouts (F1, 26=4.623, P=0.041) significantly decreased
during the night, which explains why the night time percentages
of non-REM and wake were unchanged (Table-1). The increase in
the number of bouts resulted in a significant increase (52.18 %) in
the number of transitions during the night phase (F1, 26=5.860,
P=0.023) (Table-1).
Effects on cataplexy. The number of cataplexy bouts did
not change in HCRT-ko vlPAG lesioned mice compared to
HCRT-ko mice given saline (fig. 5). In the HCRT-ko mice
cataplexy is distinct from REM sleep [25] and although the
number of REM sleep bouts increased the incidence of cataplexy
did not.
Experiment 2: Effects of vlPAG lesions in FVB-GFP
transgenic mice
Extent of lesions in FVB-GFP mice. In the FVB-GFP mice
the GFP neurons are distributed along the medial-lateral and
rostral-caudal extent of the vlPAG. First, we verified that virtually all
of the GFP labeled neurons in the vlPAG were also GABA
immunoreactive (fig. 6). Next, we determined that the vlPAG was
innervated by HCRT neurons. Injection of CTb, a retrograde
tracer, in the vlPAG resulted in retrogradely labeled somata in the
lateral hypothalamus, and some of these were HCRT neurons
(fig. 7A and B). We also observed abundant hypocretin terminals in
the vicinity of the GFP neurons in the vlPAG (fig. 7C). Most of the
Effect of vlPAG Lesions
PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6346Figure 2. Photomicrographs of NeuN staining in the control (saline injected) and lesioned (HCRT2-SAP injected in the vlPAG) HCRT-
ko mice. Compare with figure 9A which shows the localization of eGFP neurons in the vlPAG. Scale bar250 mm.
doi:10.1371/journal.pone.0006346.g002
Figure 1. Schematic representation of the extent of lesions as defined by the boundary of loss of NeuN staining in the HCRT-ko
mice. The lesions shown in A-H resulted in a significant increase in REM sleep, whereas in 3 mice (shown in I) the lesions did not significantly change
REM sleep compared to the saline injected (no lesion) HCRT-ko mice. Scale bar=1.0 mm.
doi:10.1371/journal.pone.0006346.g001
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PLoS ONE | www.plosone.org 4 July 2009 | Volume 4 | Issue 7 | e6346Figure 3. Mean (6SEM) percent REM, non-REM and wake states in HCRT-ko mice with vlPAG lesions compared to saline injected
HCRT-ko and wildtype mice. The line graphs (A, C, E) summarize the hourly average of the sleep-wake states over the 24 h period. The dark bar (A,
C, E) represents the lights-off period and the white bar represents the lights-on period of 12:12 h of the L:D cycle. The bar graphs (B, D, F) represents
the average (6SEM) REM, non-REM and wake levels during the 12 h day and night periods. *=P,0.01 for HCRT-ko saline vs. HCRT-ko vlPAG lesion, #-
represents P,0.01 for WT vs. HCRT-ko vlPAG lesion and {- represents P,0.01 WT vs. HCRT-ko saline.
doi:10.1371/journal.pone.0006346.g003
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(fig. 7D). The specificity of the antibody for the hypocretin-2
receptor has been verified [22]. To confirm in mice, we examined
another region such as the locus coeruleus where the hypocretin-1
receptor is present [26,27], and did not find hypocretin-2 receptor
immunoreactive neurons.
Since the GFP neurons were also GABA positive, these were
counted and compared between the lesioned and the unlesioned
group. However, the extent of the lesioned area was also
determined by NeuN staining. There were an average of
63.4664.81 (n=7) GFP neurons per hemisphere (AP levels24.9
to 5.2) in FVB-GFP mice given saline. Since we counted one out of
every four sections, we estimate that there are about 252 GFP
neurons in the vlPAG per hemisphere in FVB-GFP mice.
Microinjection of HCRT2-SAP (16.5 ng/23 nl) in eight of the
injected FVB-GFP mice (fig. 8A-H) resulted in an average loss of
74.41%65.17 (ranged from 55–92%; fig. 8A-H) of GFP neurons,
while in four of the mice (fig. 8I) only 7–20% of the GFP cells were
lost. These four mice were excluded from the sleep-wake data
analysis. In lesioned FVB-GFP mice (n=8) the number of GFP
neurons in the vlPAG was significantly low (two way ANOVA, for
treatment6levels, F1, 42=20.27, P,0.001) compared to saline
FVB-GFP mice (n=8). Figure 9 depicts the extent of the HCRT2-
SAP induced lesions in the FVB-GFP mice. Figure 9A is a
photomicrograph of the GFP labeled neurons in the vlPAG area of
FVB-GFP mice given saline. Figure 9B is the vlPAG area from a
representative FVB-GFP mouse given the neurotoxin and shows
the loss of the GFP neurons along with NeuN neurons. Lesions did
not encroach onto areas adjacent to the vlPAG such as the
laterodorsal tegmentum, dorsal raphe or the locus coeruleus
(fig. 9C and D).
Effect of HCRT2-SAP lesions of the vlPAG on sleep in FVB-
GFP mice
FVB-GFP mice with lesion of the vlPAG area (n=8) had
significantly more (79.09%) REM sleep (F1, 28=9.85, P=0.004)
during the night compared to FVB-GFP mice given saline
(n=8). There was no increase during the light phase. Indeed,
the lesions caused a reversal in the day-night distribution of
REM sleep so that night-time REM was higher than daytime
(Fig. 10B). Thus, the diurnal rhythm of REM sleep was changed
in that REM sleep levels at night were higher compared to day
in lesioned mice. As a result of the night time increase in REM
sleep, there was a 43.4% increase in REM sleep over the 24 h
period.
There are differences in sleep, including the diurnal rhythm of
REM sleep among the various strains of mice [28]. In the present
study, the FVB strain of mice have a blunted diurnal rhythm in
REM sleep compared to the C57BL/6J strain, but this is
consistent with a previously published report [28].
HCRT2-SAP lesions in FVB-GFP mice decreased the percentage
of time spent in non-REM sleep (two-way ANOVA, for treatment6
day/night, F1, 28=4.506, P=0.043) during the day, with no
significant differenceduring the night (fig. 10C and D). Percent wake
(two-way ANOVA, for treatment6day/night, F1, 28=9.943,
P=0.004) in the FVB-GFP lesioned mice decreased during the
night and increased in the day (fig. 10E and F). Thus, the vlPAG
lesion caused the FVB-GFP mice to be awake more during the day.
There was a significant correlation between loss of the GFP
neurons and REM sleep (r=0.889; P,0.001) and wake at night
(r=20.574; P=0.040) in the FVB-GFP lesioned mice (fig. 11).
Thus, as more GFP neurons in the vlPAG were destroyed the mice
were awake less and had more REM sleep at night.
As with lesions in the HCRT-ko mice vlPAG lesions produced a
significant increase in the number of REM bouts (F1, 14=7.762,
P=0.015) and decrease in the length of wake bouts (F1, 14=6.107,
P=0.027) during the night phase (Table-1). These lesions also
increased the number of shorter bouts (,1.3 minutes) of REM,
non-REM and wake state predominantly during the dark phase
(Fig. 12) and resulted in a trend of 58% increase in number of
transitions during the night time, similar to that seen in the
HCRT-ko mice. However, the effect on the state transitions was
not statistically significant.
Effects on cataplexy
Lesions of the vlPAG did not produce cataplexy in the FVB-
GFP transgenic mice. vlPAG lesions increased the incidence of
REM sleep bouts but there was no evidence of cataplexy.
Table 1. Effect of the HCRT-SAP induced lesions on the average (6SEM) number and length of bouts of wake, non-REM and REM
sleep.
DAY/
NIGHT Group
number of
REM bouts
length of REM
bouts (min.)
number of
NREM bouts
length of NREM
bouts (min.)
number of
Wake bouts
length of Wake
bouts (min.) Transition
DAY HCRT-KO saline (n=7) 10.0260.78 0.7560.031 19.3161.55 1.4260.12 19.3961.56 1.4360.13 583.71646.63
HCRT-KO vlPAG lesion
(n=8)
9.3261.10 0.8360.056 20.3061.33 1.1160.11 { 20.3361.34 1.6160.31 598.44642.01
FVB-GFP saline (n=8) 4.956 0.86 1.016 0.12 12.266 2.44 4.176 1.29 12.316 2.45 2.966 0.62 354.136 66.99
FVB-GFP vlPAG lesion
(n=8)
5.966 1.56 0.876 0.15 12.456 2.61 3.776 1.43 12.536 2.61 4.246 1.27 371.326 80.33
NIGHT HCRT- KO saline (n=7) 4.8260.32 0.8860.03 11.2160.78 1.4560.08 11.3260.80 3.7960.43 314.71626.81
HCRT- KO vlPAG lesion
(n=8)
6.9360.62 { 0.8860.08 16.4261.06 { 1.0960.07 { 16.6561.05 { 2.3460.25 { 478.88628.26 {
FVB-GFP saline (n=8) 3.036 0.42 1.24 60.09 7.7561.31 4.1161.07 7.7961.33 5.106 0.67 222.75635.90
FVB-GFP vlPAG lesion
(n=8)
6.1961.05* 1.2060.17 11.5862.03 3.3261.04 11.6562.04 3.0160.53 * 353.00660.56
Sleep transitions represent the tally of entries into wake, NREM and REM sleep.
*FVB-GFP vlPAG lesion vs. FVB-GFP saline; P,0.01.
{HCRT-KO saline vs. HCRT-KO-vlPAG lesion; P,0.05.
doi:10.1371/journal.pone.0006346.t001
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PLoS ONE | www.plosone.org 6 July 2009 | Volume 4 | Issue 7 | e6346Figure 4. The number and length of bouts of awake, non-REM and REM sleep in saline vs. lesioned HCRT-ko mice. Each bout of awake,
non-REM and REM sleep was placed in a bin of specific length (in minutes) of the bout. The figure represents the average (6SEM) number of bouts of
a specific length in the lesioned and saline injected HCRT-ko mice. Asterisk (*) represents p,0.01 lesioned vs. saline HCRT-ko mice.
doi:10.1371/journal.pone.0006346.g004
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The retrograde tracer cholera toxin subunit b (CTb) was
injected into the vlPAG area, either on one side or both sides
(Figure 13A’ and H’). The site and spread of the CTb is depicted
in Figure 14. The numbers of retrogradely labeled neurons were
counted on both the ipsilateral and contralateral sides (Table 2,
figure 13). Moderate to high numbers of retrogradely filled
neurons were found in the central nucleus of the amygdala,
magnocellular preoptic nucleus, preoptic area, perirhinal cortex,
ventro-medial hypothalamus (VMH), lateral hypothalamus (LH),
tuberomammillary nucleus (TMN), and lateral pontine tegmen-
tum (Figure 13A-H). Some of the CTb labeled cells in lateral
hypothalamus were immunoreactive for hypocretin (Fig. 7B) and
melanin concentrating hormone (MCH), suggesting that both
MCH and hypocretin have inputs to the vlPAG area. When the
CTb was located more caudally and encroached onto the locus
coeruleus, the numbers of retrogradely labeled neurons in the
amygdala increased (Figure 13, 14 and Table 2).
Discussion
The primary finding was that the combined deletion of HCRT
and neurons in the vlPAG exacerbated the REM sleep and sleep
fragmentation compared to deletion of HCRT by itself. However,
cataplexy, wakefulness, or non-REM sleep were unaffected. When
only the vlPAG neurons were lesioned REM sleep increased at
night, but cataplexy was not triggered. This suggests that the
lesioned neurons in the vlPAG inhibit REM sleep but not
cataplexy. Since the effects were exacerbated in HCRT-ko mice,
the vlPAG neurons receive other excitatory inputs, besides HCRT
which serves to inhibit REM sleep.
In the present study HCRT2-SAP was used to lesion vlPAG
neurons. Previously, we demonstrated that the neurotoxin binds to
HCRT receptors [6]. Briefly, Chinese hamster ovary (CHO) cells
expressing either HCRT-1 or HCRT-2 receptors were exposed to
HCRT2-SAP. As negative control, we used KNRK cells (Kirsten
murine sarcoma virus transformed Normal Rat Kidney cells)
expressing the substance-P receptor. This control tested binding of
the HCRT2-SAP to bind to other peptide receptors. Fluorescent
activated cell sorting (FACS) analysis was used and determined
that, indeed, HCRT2-SAP bound to the HCRT receptor but not
the substance-P receptor. As a positive control we determined that
substance-P-saporin bound to its receptor. We have also
demonstrated that HCRT2-SAP kills neurons in the tuberomam-
millary nucleus that contain the HCRT-2 receptor [29], whereas
the neurons in the locus coeruleus, which contain the HCRT-1
receptor are relatively resistant [12]. Even in the lateral
hypothalamus, some neurons are spared [6]. There is no evidence
that HCRT2-SAP is transported retrogradely or anterogradely to
Figure 5. Mean (6 SEM) number of cataplexy bouts during the
12 h lights-off period in lesioned and non-lesioned (saline)
HCRT-ko mice.
doi:10.1371/journal.pone.0006346.g005
Figure 6. Neurons in the vlPAG that express green fluorescent protein (GFP) are also GABA positive. FVB-TgN(GadGFP)45704Swn
transgenic mice express GFP under the control of the promoter for the gene encoding the GABA synthesizing enzyme, glutamate decarboxylase-1
(GAD-1; synonymous with GAD-67). To verify that GABA is indeed present in GFP neurons, tissue sections containing the vlPAG from these mice were
processed for immunohistochemical detection of GABA. The tissue sections were mounted onto slides and the images were obtained using a
confocal laser microscope under 606magnification. The merged image indicates that every GFP neuron also contains GABA (Yellow). Some GABA
positive neurons were not GFP positive, but this may be due to the particular type of GAD promoter used to express GFP. Scale=10 mm.
doi:10.1371/journal.pone.0006346.g006
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we did not find any observable evidence of loss of neurons in areas
adjacent to the vlPAG such as the LC or DRN. Unconjugated
saporin did not produce a degree of loss of neurons relative to the
conjugated saporin.
The vlPAG area has been lesioned in the cat [14] and rat [16]
but this is the first study to lesion it in mice. Considering that in the
present study the lesions produced a similar effect on REM sleep
in two separate strains of mice, we suggest that the lesioned
pontine area inhibits REM sleep. In the present study, the extent
of the lesioned area was based on the boundary of loss of NeuN
immunoreactivity and encompassed the vlPAG. The lesioned area
in the present study in mice was much smaller compared to the
vlPAG lesions in rats [16] indicating that a small pontine area
inhibits REM sleep. Another area lateral to the vlPAG called the
lateral pontine tegmentum (LPT) by one group [16] and the deep
mesencephalic reticular nucleus (DPMe) by another [10] is also
implicated in inhibiting REM sleep and cataplexy. In the present
study, lesions may have encroached into the LPT, but more
complete lesions of this area need to be made in HCRT-ko mice to
fully understand its role in REM sleep.
In experiment 1 HCRT-ko mice were used. These mice have
cataplexy, increased REM sleep at night, and more fragmented
sleep architecture compared to WT mice [17]. We reasoned that if
the vlPAG neurons are important regulators of REM sleep and
muscle tone then deletion of both the ligand and the target
Figure 7. Hypocretin innervation of the vlPAG. The retrograde tracer, CTb, was microinjected to the vlPAG (shown in A). In photo B, HCRT
immunoreactive neurons are identified in blue and some of these were also positive for the retrograde tracer (arrowheads in photo B) indicating
projection of HCRT neurons to the vlPAG. Photo C indicates that the vlPAG area where the GFP neurons (green) are located is traversed by hypocretin
fibers and terminals (red). The image in D shows the presence of hypocretin-2 receptor immunoreactivity (red) in the GFP neurons (as shown by the
filled arrowheads) in the vlPAG area. The unfilled arrowhead in D shows the presence of HCRT-2 receptor immunoreactivity in non-GFP labeled
neurons. Scale in A=100 mm, B=25 mm, C=10 mm, D=5 mm.
doi:10.1371/journal.pone.0006346.g007
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and cataplexy. vlPAG lesion in the HCRT-ko mice increased REM
sleep (+39% compared to HCRT-ko; +177% compared to WT),
number of bouts of REM sleep, and further fragmented sleep
architecture. The lesions did not affect cataplexy, non-REM sleep
or wakefulness.
Experiment 2 determined the effects in a system where HCRT
was present but the neurons in the vlPAG were deleted. The effects
of deletion of neurons in the vlPAG on sleep in mice are unknown.
The HCRT-ko mice used in experiment 1 have a C57BL/6J
background. Rather than lesion the vlPAG in C57BL/6J wildtype
mice, which we reasoned would only incrementally advance our
understanding of the network we chose a different strain of mice,
the FVB strain. This strain like the C57BL/6J is also an inbred
strain, but it is preferred for transgenic analysis [30]. We chose an
FVB strain where eGFP is expressed in GABA neurons [21]. We
reasoned that another strain of mice, one where the phenotype of
underlying neurons could be more easily identified with reporter
genes such as eGFP, would facilitate tract-tracing and pharma-
cology. For instance, in electrophysiology studies the eGFP
neurons could be recorded in a slice preparation to identify the
pharmacology of these neurons. Therefore, we selected the FVB
strain, since in these transgenics eGFP is driven by a murine Gad-
1 gene (one of the Gad isoforms) [21].
First, we verified that virtually all of the eGFP neurons in the
vlPAG were also GABA positive (Fig. 6), and then determined that
these neurons were also immunoreactive for the HCRT-2 receptor
antibody. A previous report identified HCRT receptor mRNA in
the vlPAG of rats [27], but in the present study immunohisto-
chemistry determined that HCRT-2 receptor was present in
eGFP/GABA neurons in the mouse vlPAG (Figure 7D). The
HCRT-receptor 2 antibody that was used has recently been tested
to be specific to HCRT-2 receptors [22]. In the present study
HCRT-2 receptor immunoreactivity was not found in the locus
coeruleus where instead the HCRT-1 receptor is present. These
verifications are a necessary first step because now these transgenic
Figure 8. Schematic representation of the extent of lesions as defined by the absence of NeuN staining and the loss of GFP neurons
in the vlPAG area of the pons in the FVB-GFP mice. The lesion extent shown in the pontine sections of the mice in A-H, significantly increased
REM sleep during the dark phase, but the lesions in some mice (n=4, the tip of the injections shown in I) did not cause significant changes in night
time REM sleep compared to the saline injected control mice. Scale21.0 mm.
doi:10.1371/journal.pone.0006346.g008
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studies to identify the role of the GABA vlPAG neurons in the
REM sleep circuit.
The second step was to determine the effects of lesion of the
vlPAG in the FVB strain of mice. vlPAG lesion in the FVB-GFP
transgenic mice produced a 79% increase in REM sleep at night,
and a 43% increase over the 24 h period compared to non-
lesioned transgenic mice. The loss of the GFP neurons in the
vlPAG was positively correlated (r=0.889) with REM sleep. The
lesioned mice also slept more at night compared to non-lesioned
mice. Lesions of the vlPAG produced a significant increase in the
number of REM sleep bouts and decrease in the length of wake
bouts during the night phase (Table-1). No bouts of cataplexy were
evident. Thus, use of the GFP transgenic line bolstered the results
from experiment 1. More importantly, this study demonstrates the
benefits of these transgenic mice in sleep studies.
Experiment 3 was performed to identify inputs to the vlPAG.
There was a prominent input from the wake active areas such as
the ventromedial hypothalamus (VMH), posterior lateral hypo-
thalamus (pLH), lateral hypothalamus (LH), tuberomammillary
nucleus (TMN) and lateral pontine tegmentum (LPT). Addition-
ally, neurons from the central nucleus of the amygdala, and
perirhinal cortex project to the vlPAG.
What is the significance of this input to the vlPAG? The
perirhinal cortex plays an important role in memory especially
with the novelty and familiarity of objects [31], and it interacts
with the hippocampus to strengthen memory [32]. The input from
the central nucleus of the amygdala would be relevant for emotion
[33]. Both of these may help direct the animal to a familiar food
source. The inputs from the VMH and LH would arouse the
animal because glucosensing neurons in these regions [34] respond
to a very narrow range of glucose levels (0.1 to 2.5 mmol/l). A
lower glucose level, which is likely at the end of a rodent’s sleep
period (during the day in nocturnal rodents), would activate
arousal neurons so that the animal can forage for food and restore
energy balance. Indeed, the HCRT neurons are activated by low
glucose levels and shut-off when the glucose levels increase [35].
Taken together, we suggest that the projections from areas
associated with memory, emotion, glucosensing and arousal
neurons would have an excitatory influence on the vlPAG GABA
neurons (Figure 15). We suggest that the activation of the vlPAG
GABA circuit prevents the animal from entering into REM sleep
thereby enabling it to maintain the proper posture and vigilance
required for foraging and feeding.
The results from experiment 3 indicate that the vlPAG neurons
receive input from a number of regions including HCRT neurons.
Together these inputs excite the vlPAG GABA neurons to inhibit
REM sleep. Considering that REM sleep was further increased
after vlPAG lesions in HCRT-ko mice is evidence that other non-
HCRT input to the vlPAG acts to inhibit REM sleep. The
Figure 9. Photomicrographs showing the loss of the GFP neurons in the control (A) and lesioned FVB-GFP mouse (B). The cells in the
lateral dorsal tegmental area (LDT) and medial dorsal raphae (DR) are spared by the lesions as shown by the NeuN staining (C), Similarly the
noradrenergic neurons of the locus coeruleus (D) are also spared by the lesion. Scale250 mm.
doi:10.1371/journal.pone.0006346.g009
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neurons, and this may also have had an additive effect.
An important finding of this study was that lesions of the vlPAG
area increased REM sleep but not cataplexy. The HCRT-2
receptor is widely present on the vlPAG neurons, including the
eGFP/GABA neurons and all of these neurons were likely lesioned
by the neurotoxin, but only REM sleep increased. Cataplexy is a
state that is distinct from REM sleep both at the behavioral and
electrophysiological level [25], and therefore the neural circuit that
triggers it is also likely to be separate. Since cataplexy was not
Figure 10. Mean (6 SEM) percent REM, non-REM and awake states in FVB-GFP mice with no lesions (saline injected) and with
HCRT2-SAP vlPAG lesions. The line graphs (A, C, E) summarize the hourly average of the sleep-wake states over the 24 h period. The dark bar (A,
C, E) represents the lights-off period and the white bar represents the lights-on period of 12:12 h of the L:D cycle. The bar graphs (B, D, F) represents
the average (6 SEM) REM, NREM and wake levels during the 12 h day and night periods. Significance levels- single asterisk (*) represents the P,0.01
for FVB-GFP saline vs. FVB-GFP vlPAG lesion.
doi:10.1371/journal.pone.0006346.g010
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doi:10.1371/journal.pone.0006346.g011
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PLoS ONE | www.plosone.org 13 July 2009 | Volume 4 | Issue 7 | e6346Figure 12. The number and length of bouts of awake, non-REM and REM sleep in saline (open circle) vs. lesioned FVB-GFP mice
(closed circle). Each bout of awake, non-REM and REM sleep was placed in a bin of specific length (in minutes) of the bout. The figure represents
the average (6 SEM) number of bouts of a specific length in the lesioned and saline injected FVB-GFP mice during the dark (A, B, C) and light phase
(D, E, F). Asterisk (*) represents p,0.01 lesioned vs. saline in FVB-GFP mice.
doi:10.1371/journal.pone.0006346.g012
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PLoS ONE | www.plosone.org 14 July 2009 | Volume 4 | Issue 7 | e6346Figure 13. Efferent input to the vlPAG area. An injection of 23 nl of 0.5% CTB in vlPAG (shown the A’) resulted in the retrolabeling of cells in the
following areas: A- Basal forebrain (Medial preoptic area): B- Basal forebrain (magnocellular preoptic area); C- Perirhinal cortex; D- ventro-medial
hypothamalus; E- lateral hypothalamus; F- tuberomammillary nucleus in the posterior hypothalamus and G- lateral pontine tegmentum. A caudal
spread of injection to the locus coeruleus was seen in two cases (shown in H’) and it resulted in retrograde labeling of cells in the amygdala as shown
in H. Scale in A’ and H’=200 mm; A-H scale=100 mm.Abbreviations: 3v- third ventricle; 4v- fourth ventricle; aq- aquaduct; CeA- central nucleus of
Amygdala; Cpu- caudate putamen; fx- fornix; GP- globus pallidus; HDB- horizontal limb of the diagonal band of broca; LC- locus coeruleus; LDT-
dorsolateral tegmentum; LDTV- ventral dorsolateral tegmentum; LH- lateral hypothalamus; LPT- lateral pontine tegmentum; MCPO- magnocellular
preoptic area; MPO- medial preoptic; ns- nigrostriatal bundle; opt- optic tract; PH- posterior hypothalamus; Pir- Piriform cortex; PRh- Perirhinal cortex;
SCN- suprachiasmatic nucleus; scp- superior cerebellar peduncle; SI- substantia innominata; TMN- tuberomammillary nucleus; vlPAG- ventrolateral
preoptic area; VMH- ventromedial hypothalamus.
doi:10.1371/journal.pone.0006346.g013
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PLoS ONE | www.plosone.org 15 July 2009 | Volume 4 | Issue 7 | e6346Figure 14. Location and spread of the retrograde tracer, cholera toxin subunit b (CTb) in the vlPAG area, as observed by the
immunohistochemistry for the CTb in the eight mice (A-H). In mice # 17–19 the CTb was injected unilaterally (right side), whereas in mice 11,
12, 13 and 21 it was injected bilaterally into the vlPAG area. In one mouse (# 21) the CTb spread caudally into the locus coeruleus as shown in H. The
numbers of retrogradelylabeled neurons in specific brain regions in each mouse is summarized in Table 2. Scale=1 mm.
doi:10.1371/journal.pone.0006346.g014
Table 2. Number of reterogradely labeled neurons in different brain areas following injection of CTb into the ventrolateral
periaquaductal gray area (vlPAG).
Mouse## 17 (A) #18 (B) #19 (C) #20 (D) #11 (E) #12 (F) #13 (G) #21 (H)
Laterality L (Contra) R (Ipsi) L (Contra) R (Ipsi) L (Contra) R (Ipsi) L (Contra) R (Ipsi) L R L R L R L R
Perirhinal Cortex – 351 – 170 – 218 – 131 43 31 178 159 154 178 177 287
Central nucleus of
Amygdala
– 1 6– 2 1– 3 3– 2 08 0 6 – 6 1 1 5 1 2 9 3 8 9
Medial preoptic area 4 25 33 59 19 94 8 37 75 47 31 33 86 117 59 66
Magnocellular preoptic
area
6 60 33 53 28 136 11 34 83 16 25 14 63 165 53 69
Ventromedial
hypothalamus
78 151 83 172 169 386 62 216 198 193 272 299 193 263 450 352
Lateral hypothalamus 14 95 33 94 108 212 7 57 109 98 67 46 122 242 162 181
Tuberomammi-llary
area
14 61 10 58 36 170 4 84 81 65 22 16 76 85 159 159
Lateral pontine
tegmentum
– 80 – 50 – 60 – 56 33 23 47 32 39 32 49 40
The CTb labeled cells were counted bilaterally in the eight mice, the site and the spread of CTb in these mice is shown in figure 14 (A-H). As shown in fig. 14, mice # 17–
20 were injected unilaterally on the right side and the table shows the counts of the labeled cells on ipsilateral and contralateral side of the CTb injection. Mice # 11, 12,
13 and 21 were injected bilaterally in vlPAG. Abbreviations: contra=contralateral to injection site; ipsi=ipsilateral to injection site; L=left; R=right.
doi:10.1371/journal.pone.0006346.t002
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lesioned (since they do not contain the HCRT receptor) or that the
cataplexy neurons are not located in the vlPAG. The second
possibility is likely since in a recent study we directly monitored the
electrophysiological activity of vlPAG neurons and did not find any
cataplexy-on neurons in the vlPAG of HCRT-ko mice [25].
What is the activity of vlPAG neurons during wake, non-REM
sleep, REM sleep and cataplexy? This question has now been
answered by our group in a study that directly monitored the
electrophysiological activity of vlPAG neurons during sleep-wake
states and cataplexy [25]. We monitored the activity of vlPAG
neurons in HCRT-ko mice and found that 64% of neurons
sampled (28 of 44) were active during both wake and REM sleep,
27% (12 of 44) were wake-active, and 9% (4 of 44) were active
during REM sleep [25]. No neurons were active during cataplexy.
Such a study has not been done in canine narcolepsy where
neuronal activity during cataplexy can also be recorded. The
range of activity across sleep-wake states is consistent with data in
the cat [36]. Thus, on the basis of electrophysiology most (40/44)
vlPAG neurons are either wake-active or wake-REM active. Since
they are active during wake they are likely driven by HCRT,
possess the HCRT receptor and lesioned in the present study.
Particularly interesting and relevant to this study was that a subset
(9%) of vlPAG neurons were more active during REM sleep
compared to waking, non-REM sleep or cataplexy. We suggest
that these neurons may be key to REM sleep generation, but not
cataplexy and their activity may underlie the increased REM sleep
in the present study. Juxtacellular recording of vlPAG neurons in
Figure 15. Model of neuronal populations that regulate wake, non-REM sleep and REM sleep (9, 13, 16). There are several neuronal
populations that are considered to generate wakefulness and these are identified in yellow. Neurons that are considered to generate non-REM sleep
are identified in blue. Both of these neuronal populations act on neurons in the pontine brainstem (red) and influence the generation of rapid-eye
movement sleep (REM sleep). Wake-on neurons inhibit REM sleep by activating pontine GABA neurons in the pons. The strength of the excitatory
input to the pontine GABA neurons influences REM sleep. A strong input will inhibit REM sleep while a weakened input will facilitate it. During non-
REM sleep the excitatory input to the pontine GABA neurons is lost and is replaced by a strong inhibitory input. This enables REM sleep generator
neurons (green) to become active and when sufficient numbers of these are activated then REM sleep ensues. In the present paper we tested this
model by lesioning the neurons in the ventral lateral periaquaductal gray area (vlPAG), and found that REM sleep was significantly increased. When
these neurons were lesioned in the hypocretin knockout mice (HCRT-ko) then the REM sleep increase was exacerbated compared to HCRT-ko mice
without vlPAG lesion. The SLD has been lesioned in rats (12,16) but not mice and there is an increase in REM sleep supporting the hypothesis of
PAIRS. Abbreviations: Ach=acetylcholine; BF=basal forebrain; DR=dorsal raphe; GABA=gamma amino butyric acid; GLUT=glutamic acid;
HA=histamine; HCRT=hypocretin; LC=locus coeruleus; LH=lateral hypothalamus; MnPO=median preoptic nucleus; NE=norepinephrine;
LDT=lateral dorsal pontine tegmentum; PPT=pedunculopontine tegmentum; SLD=sub lateral dorsal nucleus; TMN=tuberomammillary nucleus;
vlPAG=ventral lateral periaquaductal gray; VLPO=ventral lateral preoptic nucleus.
doi:10.1371/journal.pone.0006346.g015
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important to determine projections of these GFP-GABA neurons.
This is the first study to find an additive effect of deletion of both
HCRT and HCRT receptor bearing neurons in the pons. These
results underscore the importance of vlPAG neurons in regulating
REM sleep. Upon discovery of the link between HCRT and REM
sleep, initial models emphasized the role of the locus coeruleus
(LC) and the histaminergic neurons of the tuberomammillary
nucleus (TMN) in controlling REM sleep. Both the LC and the
TMN receive among the heaviest projections of HCRT neurons.
However, specific lesions of both these targets, either single lesion
or in combination (triple), do not increase REM sleep [37].
Indeed, even in mice lacking both HCRT and the norepinephrine
synthesizing enzyme, dopamine beta hydroxylase, i.e., a double
knockout, there is no additive effect [38].
The vlPAG is one pontine area that inhibits REM sleep (see
Figure 15). Another area is located in a region ventral to the locus
coeruleus and also ventral to the sub-lateral dorsal region (SLD)
[13]. Neurons in this area also inhibit REM sleep because when
we lesioned it using HCRT2-SAP there was a significant increase
in REM sleep [12]. Subsequently, other investigators found that
non-specific lesions of this region with ibotenic acid also increase
REM sleep in rats [16]. Thus, multiple pontine areas inhibit REM
sleep (Fig. 15). Because lesions of these areas and/or a hypocretin
deficiency typically increase REM sleep at night, it will be
important to determine the effects such lesions in diurnal rodents.
Supporting Information
Figure S1 Effect of unconjugated saporin (SAP) on vlPAG
neurons in a representative wildtype C57BL/6J mouse. Photo A
depicts abundant NeuN labeled neurons surrounding the SAP
microinjection site in the vlPAG. To verify that SAP was injected
green fluorescent beads (2%) were added and photo B shows
dispersal of beads at tip of injection site (photo B). Photo C is of a
bead adjacent to the perikarya of a hypocretin-2 receptor bearing
neuron (white arrow) indicating the ineffectiveness of unconjugat-
ed SAP to kill neurons relative to the conjugated version. Photos A
and B are of the same tissue section, and Photo C is from an
adjacent tissue section that was processed for visualization of the
HCRT-2 receptor.
Found at: doi:10.1371/journal.pone.0006346.s001 (4.99 MB TIF)
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